One of the nice features of dupilumab treatment is that loss of response over time seems unusual. Perhaps there is a low propensity for forming antidrug antibodies when dupilumab is used in the standard every 2-week dosing regimen. I don't know whether antidrug antibodies would be more likely with the intermittent dosing regimen. But now that we have other good systemic treatment options for AD, losing dupilumab efficacy would not be as critical a problem as it used to be. I also want to point out that patients' adherence to injection treatment, though better than adherence to topicals, is far from perfect. It's likely that many patients have already been prolonging the interval between taking their treatments. If you want to know, just ask them. The way I like to phrase the question is: "Are you keeping the extra injectors you've accumulated refrigerated like you are supposed to?"
Clinical Edge Journal Scan
Commentary: Topical treatments, dupilumab, and long-term treatment of AD, July 2023
- Commentary: AD, RA, Probiotics, and a New JAK inhibitor, June 2023
- Upadacitinib shows a favorable benefit-risk profile in adolescents with moderate-to-severe atopic dermatitis
- Tralokinumab effective against moderate-to-severe atopic dermatitis in adolescents
- Crisaborole induces normalization of mild-to-moderate atopic dermatitis proteome
- Real-world study affirms benefits of dupilumab in pediatric patients with uncontrolled atopic dermatitis
- A new emollient regimen improves pruritus in atopic dermatitis
- Tralokinumab effective against moderate-to-severe atopic dermatitis in daily practice
- An emollient plus balm offers corticosteroid-sparing effects in mild-to-moderate atopic dermatitis
- Meta-analysis shows unidirectional association between atopic dermatitis and rheumatoid arthritis
- Low diversity in skin microbiome in infancy raises risk for atopic dermatitis in high-risk children
- Single-strain probiotic lactobacilli: An up-and-coming adjuvant therapy for atopic dermatitis
Next Article:
- Commentary: AD, RA, Probiotics, and a New JAK inhibitor, June 2023
- Upadacitinib shows a favorable benefit-risk profile in adolescents with moderate-to-severe atopic dermatitis
- Tralokinumab effective against moderate-to-severe atopic dermatitis in adolescents
- Crisaborole induces normalization of mild-to-moderate atopic dermatitis proteome
- Real-world study affirms benefits of dupilumab in pediatric patients with uncontrolled atopic dermatitis
- A new emollient regimen improves pruritus in atopic dermatitis
- Tralokinumab effective against moderate-to-severe atopic dermatitis in daily practice
- An emollient plus balm offers corticosteroid-sparing effects in mild-to-moderate atopic dermatitis
- Meta-analysis shows unidirectional association between atopic dermatitis and rheumatoid arthritis
- Low diversity in skin microbiome in infancy raises risk for atopic dermatitis in high-risk children
- Single-strain probiotic lactobacilli: An up-and-coming adjuvant therapy for atopic dermatitis